Evinova, an AstraZeneca‑established AI‑native clinical development platform, signed agreements allowing Astellas, Bristol Myers Squibb and AstraZeneca to use its systems for study design optimization and document management. The pharma partners will share operational trial data in exchange for benchmarking and AI recommendations intended to accelerate timelines and improve study performance. Evinova framed the deals as enterprise collaborations rather than pilot projects, reflecting industry demand for AI‑driven trial orchestration. The partnerships may increase adoption of AI tools in operational decision‑making but also raise questions about data governance and performance benchmarking across sponsors and CROs.